Sarepta Therapeutics Inc (NASDAQ: SRPT)’s stock price has decreased by -6.00 compared to its previous closing price of 43.01. However, the company has seen a 7.13% increase in its stock price over the last five trading sessions. zacks.com reported 2025-06-05 that Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What’s next for the stock?
Is It Worth Investing in Sarepta Therapeutics Inc (NASDAQ: SRPT) Right Now?
Moreover, the 36-month beta value for SRPT is 0.60. Analysts have varying opinions on the stock, with 14 analysts rating it as a “buy,” 8 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for SRPT is 93.37M and currently, short sellers hold a 9.45% of that float. On June 09, 2025, SRPT’s average trading volume was 3.66M shares.
SRPT’s Market Performance
SRPT’s stock has seen a 7.13% increase for the week, with a 10.71% rise in the past month and a -59.44% fall in the past quarter. The volatility ratio for the week is 4.29%, and the volatility levels for the past 30 days are at 3.16% for Sarepta Therapeutics Inc The simple moving average for the past 20 days is 5.66% for SRPT’s stock, with a -59.83% simple moving average for the past 200 days.
Analysts’ Opinion of SRPT
Evercore ISI, on the other hand, stated in their research note that they expect to see SRPT reach a price target of $50. The rating they have provided for SRPT stocks is “In-line” according to the report published on May 08th, 2025.
Wells Fargo gave a rating of “Overweight” to SRPT, setting the target price at $115 in the report published on April 11th of the current year.
SRPT Trading at -17.14% from the 50-Day Moving Average
After a stumble in the market that brought SRPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.66% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at SRPT starting from Nicaise Claude, who sale 2,491 shares at the price of $99.64 back on Mar 12 ’25. After this action, Nicaise Claude now owns 27,812 shares of Sarepta Therapeutics Inc, valued at $248,203 using the latest closing price.
Nicaise Claude, the Director of Sarepta Therapeutics Inc, proposed sale 2,491 shares at $99.65 during a trade that took place back on Mar 12 ’25, which means that Nicaise Claude is holding shares at $248,226 based on the most recent closing price.
Stock Fundamentals for SRPT
Current profitability levels for the company are sitting at:
- -0.05 for the present operating margin
- 0.81 for the gross margin
The net margin for Sarepta Therapeutics Inc stands at -0.11. The total capital return value is set at -0.04. Equity return is now at value -23.61, with -7.43 for asset returns.
Based on Sarepta Therapeutics Inc (SRPT), the company’s capital structure generated 0.54 points at debt to capital in total, while cash flow to debt ratio is standing at -0.41. The debt to equity ratio resting at 1.18. The interest coverage ratio of the stock is -6.26.
Currently, EBITDA for the company is 333.06 million with net debt to EBITDA at -9.37. When we switch over and look at the enterprise to sales, we see a ratio of 2.27. The receivables turnover for the company is 3.08for trailing twelve months and the total asset turnover is 0.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.02.
Conclusion
To wrap up, the performance of Sarepta Therapeutics Inc (SRPT) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
